⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094430 | 0.72 | — | — | |
| SCHEMBL789751 | 0.70 | — | — | |
| SCHEMBL2225750 | 0.70 | — | — | |
| SCHEMBL15094216 | 0.70 | — | — | |
| SCHEMBL10963089 | 0.70 | — | — | |
| SCHEMBL7609834 | 0.67 | MEN1 (0.38) | — | |
| SCHEMBL3289818 | 0.67 | TSHR (0.32) | — | |
| SCHEMBL7400295 | 0.65 | — | — | |
| SCHEMBL749761 | 0.65 | — | — | |
| SCHEMBL105871 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807266-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2021-04-21 | — | — | EP | claimed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | claimed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | claimed |
| US-9416106-B2 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2016-08-16 | — | — | US | claimed |
| US-20150368201-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2015-12-24 | — | — | US | claimed |
| US-9120750-B2 | 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2015-09-01 | — | — | US | claimed |
| WO-2014138460-A1 | 2-AMINOPYRIDINE-BASED SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140256016-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2014-09-11 | — | — | US | claimed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| EP-3807266-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20150368201-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2015-12-24 | — | — | US | disclosed |
| US-9120750-B2 | 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2014138460-A1 | 2-AMINOPYRIDINE-BASED SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256016-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |